Harald Nusser

Harald Nusser

Harald Nusser is the head of global patient solutions at Gilead Sciences, working on sustainable business models to ensure that medicines are affordable and accessible around the world. He is also a global ambassador of the G20 Health & Development Partnership. Prior to joining Gilead, Harald was head of Novartis Social Business, and he supported The Defeat-NCD Partnership as a board member in 2018. Harald also spent 10 years at Bayer Pharmaceuticals and six years at Schering Pharmaceuticals. He holds a Ph.D. in Mathematics from Freie Universität Berlin and an Executive MBA from the University of Bradford.

Latest Articles

Opinion: Searching for the next generation of sustainable health care

Opinion: Searching for the next generation of sustainable health care

about 4 years ago // Sponsored by Gilead

What should a new era of progress in global health look like and how can it be ushered in? Gilead's Harald Nusser shares some takeaways from a recent event on the topic.

Opinion: The coming evaluation revolution in corporate responsibility

Opinion: The coming evaluation revolution in corporate responsibility

about 7 years ago // Produced in Partnership: Taking the Pulse

Most companies want their corporate responsibility programs to work, but few develop the evidence base to understand whether they actually do. Experts weigh in on how to achieve social change at scale.

Opinion: African experts warn big changes needed to eliminate malaria

Opinion: African experts warn big changes needed to eliminate malaria

over 7 years ago // Sponsored by Novartis

A new independent policy study, commissioned by Novartis, reveals controversial views about what African experts think is the best way to push forward progress on malaria eliminations. This guest column details the biggest findings of the Malaria Futures for Africa, or MalaFA study, and explains why we need to take advantage of these African insights and learnings.

How new business models can help fight chronic diseases

How new business models can help fight chronic diseases

over 9 years ago // Access To Medicines

Health systems in lower-income countries must now cope with the new epidemic of chronic diseases without losing focus of the ongoing fight against infectious diseases, asserts Harald Nusser, global head at Novartis Access, in this #Access2Meds guest column.